In the recent round of topic allocations HEDS was given one NICE single technology appraisal (STA). It is ridaforolimus (brand name unknown!) for the first-line maintenance treatment of metastatic soft tissue or bone sarcoma. The draft scope is available here.
For further information contact Eva Kaltenthaler or Matt Stevenson.